Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients with ST-Elevation Myocardial Infarction: Analysis from the CELEBRATE Trial.
Renal impairment portends higher rates of clinical events and bleeding among patients with ST-segment elevation myocardial infarction (STEMI). Zalunfiban is a novel, subcutaneous glycoprotein IIb/IIIa inhibitor designed for pre-hospital administration. This post hoc analysis of the CELEBRATE trial evaluated the efficac...